Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366085929> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4366085929 endingPage "2133" @default.
- W4366085929 startingPage "2125" @default.
- W4366085929 abstract "Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with pemetrexed and cisplatin results in survival time superior to that achieved with cisplatin alone.Chemotherapy-naive patients who were not eligible for curative surgery were randomly assigned to receive pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1, or cisplatin 75 mg/m2 on day 1. Both regimens were given intravenously every 21 days.A total of 456 patients were assigned: 226 received pemetrexed and cisplatin, 222 received cisplatin alone, and eight never received therapy. Median survival time in the pemetrexed/cisplatin arm was 12.1 months versus 9.3 months in the control arm (P = .020, two-sided log-rank test). The hazard ratio for death of patients in the pemetrexed/cisplatin arm versus those in the control arm was 0.77. Median time to progression was significantly longer in the pemetrexed/cisplatin arm: 5.7 months versus 3.9 months (P = .001). Response rates were 41.3% in the pemetrexed/cisplatin arm versus 16.7% in the control arm (P < .0001). After 117 patients had enrolled, folic acid and vitamin B12 were added to reduce toxicity, resulting in a significant reduction in toxicities in the pemetrexed/cisplatin arm.Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cisplatin alone in patients with malignant pleural mesothelioma. Addition of folic acid and vitamin B12 significantly reduced toxicity without adversely affecting survival time." @default.
- W4366085929 created "2023-04-19" @default.
- W4366085929 creator A5007889470 @default.
- W4366085929 creator A5014079935 @default.
- W4366085929 creator A5035737598 @default.
- W4366085929 creator A5052459898 @default.
- W4366085929 creator A5058811308 @default.
- W4366085929 creator A5059219836 @default.
- W4366085929 creator A5059850025 @default.
- W4366085929 creator A5060335134 @default.
- W4366085929 creator A5062933842 @default.
- W4366085929 creator A5063125365 @default.
- W4366085929 creator A5064962179 @default.
- W4366085929 creator A5077287358 @default.
- W4366085929 date "2023-04-20" @default.
- W4366085929 modified "2023-10-18" @default.
- W4366085929 title "Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma" @default.
- W4366085929 doi "https://doi.org/10.1200/jco.22.02542" @default.
- W4366085929 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37068377" @default.
- W4366085929 hasPublicationYear "2023" @default.
- W4366085929 type Work @default.
- W4366085929 citedByCount "2" @default.
- W4366085929 countsByYear W43660859292023 @default.
- W4366085929 crossrefType "journal-article" @default.
- W4366085929 hasAuthorship W4366085929A5007889470 @default.
- W4366085929 hasAuthorship W4366085929A5014079935 @default.
- W4366085929 hasAuthorship W4366085929A5035737598 @default.
- W4366085929 hasAuthorship W4366085929A5052459898 @default.
- W4366085929 hasAuthorship W4366085929A5058811308 @default.
- W4366085929 hasAuthorship W4366085929A5059219836 @default.
- W4366085929 hasAuthorship W4366085929A5059850025 @default.
- W4366085929 hasAuthorship W4366085929A5060335134 @default.
- W4366085929 hasAuthorship W4366085929A5062933842 @default.
- W4366085929 hasAuthorship W4366085929A5063125365 @default.
- W4366085929 hasAuthorship W4366085929A5064962179 @default.
- W4366085929 hasAuthorship W4366085929A5077287358 @default.
- W4366085929 hasConcept C126322002 @default.
- W4366085929 hasConcept C141071460 @default.
- W4366085929 hasConcept C142724271 @default.
- W4366085929 hasConcept C143998085 @default.
- W4366085929 hasConcept C2776694085 @default.
- W4366085929 hasConcept C2777240266 @default.
- W4366085929 hasConcept C2777407522 @default.
- W4366085929 hasConcept C2778239845 @default.
- W4366085929 hasConcept C71924100 @default.
- W4366085929 hasConcept C90924648 @default.
- W4366085929 hasConceptScore W4366085929C126322002 @default.
- W4366085929 hasConceptScore W4366085929C141071460 @default.
- W4366085929 hasConceptScore W4366085929C142724271 @default.
- W4366085929 hasConceptScore W4366085929C143998085 @default.
- W4366085929 hasConceptScore W4366085929C2776694085 @default.
- W4366085929 hasConceptScore W4366085929C2777240266 @default.
- W4366085929 hasConceptScore W4366085929C2777407522 @default.
- W4366085929 hasConceptScore W4366085929C2778239845 @default.
- W4366085929 hasConceptScore W4366085929C71924100 @default.
- W4366085929 hasConceptScore W4366085929C90924648 @default.
- W4366085929 hasIssue "12" @default.
- W4366085929 hasLocation W43660859291 @default.
- W4366085929 hasLocation W43660859292 @default.
- W4366085929 hasOpenAccess W4366085929 @default.
- W4366085929 hasPrimaryLocation W43660859291 @default.
- W4366085929 hasRelatedWork W1978520323 @default.
- W4366085929 hasRelatedWork W2009040992 @default.
- W4366085929 hasRelatedWork W2083305999 @default.
- W4366085929 hasRelatedWork W2162580433 @default.
- W4366085929 hasRelatedWork W2222520153 @default.
- W4366085929 hasRelatedWork W2413537020 @default.
- W4366085929 hasRelatedWork W2591408645 @default.
- W4366085929 hasRelatedWork W2953220268 @default.
- W4366085929 hasRelatedWork W2953636941 @default.
- W4366085929 hasRelatedWork W3205509964 @default.
- W4366085929 hasVolume "41" @default.
- W4366085929 isParatext "false" @default.
- W4366085929 isRetracted "false" @default.
- W4366085929 workType "article" @default.